A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
pharmacodynamics of ALN-CC5 in healthy adult volunteers and subjects with PNH